Phase III, Randomized, Placebo-Controlled Study of Docetaxel in Combination With Zibotentan in Patients With Metastatic Castration-Resistant Prostate Cancer

Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostrate cancer: A phase I/II, open-label study.

(2017) R. Dreicer et al.   JOURNAL OF CLINICAL ONCOLOGY

Automated telephone reminders: Potential to improve adherence to adjuvant hormonal therapy among patients with breast cancer.

(2017) Virginia P. Quinn et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I/II safety and pharmacokinetic (PK) study of ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase I results of a Prostate Cancer Clinical Trials Consortium study.

(2017) Dana E. Rathkopf et al.   JOURNAL OF CLINICAL ONCOLOGY

Recent developments in treatments targeting castration-resistant prostate cancer bone metastases

(2012) Y. Loriot et al.   ANNALS OF ONCOLOGY

Young Oncologists

(2012)   ANNALS OF ONCOLOGY

Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone

(2012) Joel B. Nelson et al.   CANCER

Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401

(2012) William Kevin Kelly et al.   JOURNAL OF CLINICAL ONCOLOGY

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

(2012) Karim Fizazi et al.   LANCET ONCOLOGY

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

(2012) Howard I. Scher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Role of the endothelin axis and its antagonists in the treatment of cancer

(2011) A Bagnato et al.   BRITISH JOURNAL OF PHARMACOLOGY

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Targeting Continued Androgen Receptor Signaling in Prostate Cancer

(2011) C. Massard et al.   CLINICAL CANCER RESEARCH

Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA)

(2011) C. Parker et al.   EUROPEAN JOURNAL OF CANCER

Randomized, Open-Label Phase III Trial of Docetaxel Plus High-Dose Calcitriol Versus Docetaxel Plus Prednisone for Patients With Castration-Resistant Prostate Cancer

(2011) Howard I. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

(2011) Karim Fizazi et al.   LANCET

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

(2011) Matthew R Smith et al.   LANCET

Abiraterone and Increased Survival in Metastatic Prostate Cancer

(2011) Johann S. de Bono et al.   NEW ENGLAND JOURNAL OF MEDICINE

Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer

(2010) S. Rajpar et al.   ANNALS OF ONCOLOGY

Docetaxel-based combination therapy for castration-resistant prostate cancer

(2010) M. D. Galsky et al.   ANNALS OF ONCOLOGY

Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind,

(2010) Nicholas D. James et al.   BJU INTERNATIONAL

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

(2010) Johann Sebastian de Bono et al.   LANCET

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Importance of Identifying and Validating Prognostic Factors in Oncology

(2010) Susan Halabi et al.   SEMINARS IN ONCOLOGY

Denosumab Treatment of Prostate Cancer With Bone Metastases and Increased Urine N-Telopeptide Levels After Therapy With Intravenous Bisphosphonates: Results of a Randomized Phase II Trial

(2009) Karim Fizazi et al.   JOURNAL OF UROLOGY

Measuring therapeutic efficacy in the changing paradigm of castrate-resistant prostate cancer

(2009) P F Mulders et al.   PROSTATE CANCER AND PROSTATIC DISEASES

A Phase I-II Study of Docetaxel and Atrasentan in Men with Castration-Resistant Metastatic Prostate Cancer

(2008) A. J. Armstrong et al.   CLINICAL CANCER RESEARCH

Safety and Efficacy of the Specific Endothelin-A Receptor Antagonist ZD4054 in Patients with Hormone-Resistant Prostate Cancer and Bone Metastases Who Were Pain Free or Mildly Symptomatic: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 Trial

(2008) Nicholas D. James et al.   EUROPEAN UROLOGY

Challenges and Opportunities in Hormone-Resistant Prostate Cancer

(2008) Kurt Miller   EUROPEAN UROLOGY SUPPLEMENTS